DDInter1233 DDInter1959
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia.
Mitotane {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Mitotane {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Mitotane {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Mitotane {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is downregulated by {v} (Compound) Treprostinil
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Mitotane {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Mitotane {u} (Compound) resembles {v} (Compound) Butoconazole
Butoconazole {u} (Compound) resembles {v} (Compound) Miconazole
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
CYP11B1 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Mitotane (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Mitotane (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Mitotane (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may lead to a major life threatening interaction when taken with Zanubrutinib
Mitotane (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is downregulated by Treprostinil (Compound) and Treprostinil may lead to a major life threatening interaction when taken with Zanubrutinib
Mitotane (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Zanubrutinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Mitotane (Compound) resembles Butoconazole (Compound) and Butoconazole (Compound) resembles Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Mitotane (Compound) binds CYP11B1 (Gene) and CYP11B1 (Gene) is bound by Fluconazole (Compound) and Fluconazole may lead to a major life threatening interaction when taken with Zanubrutinib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib